|
US8877780B2
(en)
*
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
CL2007002513A1
(es)
*
|
2006-08-30 |
2008-04-04 |
Celgene Corp Soc Organizada Ba |
Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
|
|
CL2007002499A1
(es)
|
2006-08-30 |
2008-03-14 |
Phenomix Corp |
Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
|
|
PT2358697E
(pt)
*
|
2008-10-29 |
2016-02-03 |
Celgene Corp |
Compostos de isoindolina para utilização no tratamento do cancro
|
|
EP2699091B1
(en)
|
2011-03-28 |
2017-06-21 |
DeuteRx, LLC |
2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
|
|
JP6359563B2
(ja)
|
2013-01-14 |
2018-07-18 |
デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ |
３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
|
|
CA2941560A1
(en)
|
2013-03-14 |
2014-09-25 |
Deuterx, Llc |
3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
|
|
UA117141C2
(uk)
|
2013-10-08 |
2018-06-25 |
Селджин Корпорейшн |
Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
|
|
WO2015085172A2
(en)
|
2013-12-06 |
2015-06-11 |
Celgene Corporation |
Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
|
|
RU2738833C9
(ru)
*
|
2014-04-14 |
2022-02-28 |
Арвинас, Оперэйшнз, Инк. |
Имидные модуляторы протеолиза и способы их применения
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US9499514B2
(en)
*
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
WO2016057503A1
(en)
*
|
2014-10-07 |
2016-04-14 |
Celgene Corporation |
Use of biomarkers for predicting clinical sensitivity to cancer treatment
|
|
WO2016105518A1
(en)
*
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
US9809603B1
(en)
|
2015-08-18 |
2017-11-07 |
Deuterx, Llc |
Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
|
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
SG11201805779TA
(en)
*
|
2016-01-08 |
2018-08-30 |
Celgene Corp |
Antiproliferative compounds, and their pharmaceutical compositions and uses
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
US10759808B2
(en)
*
|
2016-04-06 |
2020-09-01 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
|
ES2990061T3
(es)
|
2016-05-10 |
2024-11-28 |
C4 Therapeutics Inc |
Degronímeros espirocíclicos para la degradación de proteínas diana
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
EP3454856B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
CN110506039A
(zh)
|
2016-10-11 |
2019-11-26 |
阿尔维纳斯股份有限公司 |
用于雄激素受体靶向降解的化合物和方法
|
|
MX2019005007A
(es)
|
2016-11-01 |
2019-07-18 |
Arvinas Inc |
Protac dirigidos a la proteína tau y métodos asociados de uso.
|
|
BR112019011200B1
(pt)
|
2016-12-01 |
2021-12-28 |
Arvinas Operations, Inc |
Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
|
|
JP2020505327A
(ja)
|
2016-12-23 |
2020-02-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
KR20250117470A
(ko)
|
2016-12-23 |
2025-08-04 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
BR112019015312A2
(pt)
*
|
2017-01-26 |
2020-03-10 |
Arvinas Operations, Inc. |
Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados
|
|
IL312367A
(en)
|
2017-01-31 |
2024-06-01 |
Arvinas Operations Inc |
Cereblon ligands and bifunctional compounds comprising the same
|
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
WO2019043217A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROBENZIMIDAZOLONES
|
|
CN118108706A
(zh)
|
2017-09-04 |
2024-05-31 |
C4医药公司 |
戊二酰亚胺
|
|
WO2019043208A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROQUINOLINONES
|
|
CN111372585A
(zh)
|
2017-11-16 |
2020-07-03 |
C4医药公司 |
用于靶蛋白降解的降解剂和降解决定子
|
|
EP3710443A1
(en)
|
2017-11-17 |
2020-09-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
WO2019148055A1
(en)
|
2018-01-26 |
2019-08-01 |
Yale University |
Imide-based modulators of proteolysis and methods of use
|
|
EP3773576A4
(en)
|
2018-03-26 |
2021-12-29 |
C4 Therapeutics, Inc. |
Cereblon binders for the degradation of ikaros
|
|
WO2019195609A2
(en)
|
2018-04-04 |
2019-10-10 |
Arvinas Operations, Inc. |
Modulators of proteolysis and associated methods of use
|
|
EP3781156A4
(en)
|
2018-04-16 |
2022-05-18 |
C4 Therapeutics, Inc. |
SPIROCYCLIC COMPOUNDS
|
|
FI3784663T3
(fi)
|
2018-04-23 |
2023-10-06 |
Celgene Corp |
Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
JP7297053B2
(ja)
|
2018-08-20 |
2023-06-23 |
アルビナス・オペレーションズ・インコーポレイテッド |
神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
|
|
AU2019348094B2
(en)
|
2018-09-30 |
2022-12-22 |
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences |
Isoindoline compound, preparation method, pharmaceutical composition and use thereof
|
|
WO2020102195A1
(en)
|
2018-11-13 |
2020-05-22 |
Biotheryx, Inc. |
Substituted isoindolinones
|
|
WO2020114482A1
(zh)
|
2018-12-06 |
2020-06-11 |
中国科学院上海药物研究所 |
一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
|
|
CN120698983A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
ES2995214T3
(en)
|
2019-03-06 |
2025-02-07 |
C4 Therapeutics Inc |
Heterocyclic compounds for medical treatment
|
|
WO2020210630A1
(en)
|
2019-04-12 |
2020-10-15 |
C4 Therapeutics, Inc. |
Tricyclic degraders of ikaros and aiolos
|
|
KR102913106B1
(ko)
|
2019-05-31 |
2026-01-19 |
셀진 코포레이션 |
치환된 1-옥소-이소인돌린-5-카르복스아미드 화합물, 그의 조성물 및 그를 사용한 치료 방법
|
|
EP3999182A1
(en)
|
2019-07-17 |
2022-05-25 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated methods of use
|
|
KR20220054347A
(ko)
|
2019-08-26 |
2022-05-02 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
|
|
WO2021069705A1
(en)
*
|
2019-10-09 |
2021-04-15 |
Monte Rosa Therapeutics |
Isoindolinone compounds
|
|
CA3154386A1
(en)
|
2019-10-17 |
2021-04-22 |
Michael Berlin |
Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety
|
|
JP7852923B2
(ja)
|
2019-11-27 |
2026-04-28 |
キャプター セラピューティクス エス．エー． |
セレブロンに結合するピペリジン－２，６－ジオン誘導体、及びその使用方法
|
|
WO2021105335A1
(en)
|
2019-11-27 |
2021-06-03 |
Captor Therapeutics S.A. |
Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
|
|
AU2020405129A1
(en)
|
2019-12-19 |
2022-06-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
CR20220630A
(es)
|
2020-05-09 |
2023-01-23 |
Arvinas Operations Inc |
Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
|
|
US20240294489A1
(en)
*
|
2020-08-03 |
2024-09-05 |
Captor Therapeutics S.A. |
Low molecular weight protein degraders and their applications
|
|
WO2022047145A1
(en)
|
2020-08-28 |
2022-03-03 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
WO2022056368A1
(en)
|
2020-09-14 |
2022-03-17 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of estrogen receptor
|
|
EP4217352A4
(en)
*
|
2020-09-23 |
2024-04-10 |
St. Jude Children's Research Hospital, Inc. |
Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
|
|
WO2022146151A1
(en)
|
2020-12-30 |
2022-07-07 |
Captor Therapeutics S.A. |
Novel compounds which bind to cereblon, and methods of use thereof
|
|
AU2022207648A1
(en)
|
2021-01-13 |
2023-07-27 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
|
WO2022200857A1
(en)
*
|
2021-03-22 |
2022-09-29 |
Monte Rosa Therapeutics Ag |
Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons
|
|
KR20230171979A
(ko)
|
2021-04-16 |
2023-12-21 |
아비나스 오퍼레이션스, 인코포레이티드 |
Bcl6 단백질 분해의 조절제 및 관련 사용 방법
|
|
WO2022255889A1
(en)
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Compounds which bind to cereblon, and use thereof
|
|
WO2022255890A1
(en)
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Compounds which bind to cereblon, and use thereof
|
|
JP2024544507A
(ja)
*
|
2021-11-09 |
2024-12-03 |
コリア リサーチ インスティテュート オブ ケミカル テクノロジー |
グルタルイミド母核を有するイソインドリノン誘導体及びその用途
|
|
CA3249074A1
(en)
|
2022-06-06 |
2023-12-14 |
C4 Therapeutics, Inc. |
BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS
|
|
WO2024015618A2
(en)
*
|
2022-07-15 |
2024-01-18 |
St. Jude Children's Research Hospital, Inc. |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione/2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione analogs as modulators of cereblon protein
|
|
WO2024054591A1
(en)
|
2022-09-07 |
2024-03-14 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
KR20240066904A
(ko)
*
|
2022-11-08 |
2024-05-16 |
주식회사 온코드바이오 |
아릴시클로알킬아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도
|
|
US12448399B2
(en)
|
2023-01-26 |
2025-10-21 |
Arvinas Operations, Inc. |
Cereblon-based KRAS degrading PROTACs and uses related thereto
|
|
WO2024167423A1
(en)
|
2023-02-07 |
2024-08-15 |
Captor Therapeutics S.A. |
Gspt1 degrader compounds
|
|
KR102570883B1
(ko)
*
|
2023-04-13 |
2023-08-29 |
(주) 사이러스테라퓨틱스 |
신규한 gspt1 분해제 및 이의 용도
|
|
TW202535392A
(zh)
|
2023-12-08 |
2025-09-16 |
美商亞文納營運公司 |
使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮
|